LMP-744

N/A

Report date: 2026/02/25 20:02:36
NME

Base Information

Drug NameLMP-744
Drug Alias NameLMP-744NSC-706744MJ-III-65
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursBrain Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstitutePurdue UniversityLinus Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteNational Institute Of Neurological Disorders And StrokeGibson Oncology LLC
Inactive CompaniesN/A
Active IndicationsCNS Embryonal TumorSolid tumoursBrain Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A